The DOI matches its Crossref record.
Phosphinic Acid Analogs of GABA. 2. Selective, Orally Active GABAB Antagonists
Open accessAbstract
In 1987, 25 years after the synthesis of the potent and selective GABAB agonist baclofen (1), Kerr et al. described the first GABAB antagonist phaclofen 2. However, phaclofen and structurally similar derivatives 3-5 did not cross the blood-brain barrier and hence were inactive in vivo as central nervous system agents. As a consequence, the therapeutic potential of GABAB antagonists remained unclear. In exploring GABA and baclofen derivatives by replacing the carboxylic acid residue with various phosphinic acid groups, we discovered more potent and water soluble GABAB antagonists. Electrophysiological experiments in vivo demonstrated that some of the new compounds were capable of penetrating the blood-brain barrier after oral administration. Neurotransmitter release experiments showed that they interacted with several presynaptic GABAB receptor subtypes, enhancing the release of GABA, glutamate, aspartate, and somatostatin. The new GABAB antagonists interacted also with postsynaptic GABAB receptors, as they blocked late inhibitory postsynaptic potentials. They facilitated the induction of long-term potentiation in vitro and in vivo, suggesting potential cognition enhancing effects. Fifteen compounds were investigated in various memory and learning paradigms in rodents. Although several compounds were found to be active, only 10 reversed the age-related deficits of old rats in a multiple-trial one-way active avoidance test after chronic treatment. The cognition facilitating effects of 10 were confirmed in learning experiments in Rhesus monkeys. The novel GABAB antagonists showed also protective effects in various animal models of absence epilepsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bowery, N. G., Bettler, B., Froestl, W., Gallagher, J. P., Marshall, F., Raiteri, M., Bonner, T. I., & Enna, S. J. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.247 · Cited by 601
Self-citationMombereau, C., Kaupmann, K., Froestl, W., Sansig, G., van der Putten, H., & Cryan, J. F. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300413 · Cited by 350
Self-citationEnna, S. J. (2007) · The Receptors · doi:10.1007/978-1-59745-465-0_1 · Cited by 266
Effects of GABAB receptor agonists and antagonists on glycemia regulation in mice
Bonaventura, M. M., Crivello, M., Ferreira, M. L., Repetto, M., Cymeryng, C., Libertun, C., & Lux-Lantos, V. A. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.12.013 · Cited by 19
Metadata
- Authors
- Froestl, W., Mickel, S. J., von Sprecher, G., Diel, P. J., Hall, R. G., Maier, L., Strub, D., Melillo, V., & Baumann, P. A.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1995-08
- Volume
- 38
- Issue
- 17
- Pages
- 3313-3331
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2092845873
- Cited by
- 207
- References
- 0
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phosphinic Acid Analogs of GABA. 2. Selective, Orally Active GABAB Antagonists. https://app.cochat.ai/papers/10.1021/jm00017a016
- The paper
- Froestl, W., Mickel, S. J., von Sprecher, G., Diel, P. J., Hall, R. G., Maier, L., Strub, D., Melillo, V., & Baumann, P. A. (1995). Phosphinic Acid Analogs of GABA. 2. Selective, Orally Active GABAB Antagonists. Journal of Medicinal Chemistry. https://doi.org/10.1021/jm00017a016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.